Funding Announcement: Serpenta Secures $250K in Pre-Seed Round for Revolutionary Medical Robot Development

Serpenta, a pioneering start-up dedicated to disrupting the landscape of endoluminal surgery, is thrilled to announce that we have successfully raised $250,000 in our latest funding round. Specializing in the development of soft and continuum medical robots with fluidic actuation, we are on a mission to transform the future of surgical procedures, particularly in the lower gastrointestinal (GI) region. Our core innovation, the bi-manual snake-robot, is currently in development and designed specifically for colorectal cancer treatment. The advanced capabilities of our robot are set to enable endoscopic submucosal dissection (ESD) to be performed at a scale never seen before, ensuring high precision and low risk during these delicate procedures. The design of our robot, based on a patented concept developed by our CTO during his doctorate at Imperial College London, is being expanded to create a full-fledged device that promises dexterity and flexibility in navigating the colon. This funding will play a crucial role in accelerating our research and development efforts, allowing us to bring this revolutionary technology closer to market. Our vision is clear: we aim to lower the risks, costs, and complications often associated with lower GI surgeries, ultimately leading to improved patient outcomes. As we move forward, we are grateful for the support of our investors and excited to take the next steps in realizing our ambitious goals for the benefit of patients and the medical community alike.